COMMENTARY

• Further Research Needed to Advance the Use of Regulatory Science in Regulatory Affairs
  November 14, 2011

• Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
  October 19, 2011

• Pinning Hope on Academia in Seeking a Radical Cure for AD
  October 10, 2011

• New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain
  October 3, 2011

• Discussions on Amendment of PAL Now in Final Stages
  October 3, 2011

• Korosho Revises GL for Drafting, Distributing Drug Safety Information
  September 5, 2011

• Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
  August 29, 2011

• Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
  August 8, 2011

• Current Promising Drug Candidates with a New Mode of Action
  August 8, 2011

• Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
  July 18, 2011

• Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
  July 4, 2011

• Era of Competition Dawns in Market for AD Treatments
  June 27, 2011

• Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
  June 20, 2011

• Return to Full-bore Growth Strategy Risky for Taiyo Pharm
  June 13, 2011

• Why the Same Mistake Repeated? -MSD's Promotion Code Violations
  June 6, 2011

• GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
  June 6, 2011

• Effects of Changes to Accelerate Approval to Be Seen from November
  May 30, 2011

• Japan's Most Admired Pharma Companies in 2010
  April 4, 2011

• Will New Disclosure GL Promote Industry-Academia Alliances?
  March 28, 2011

• Use of Generics by Welfare Recipients
  March 7, 2011

ページ